Key facts
- This page summarizes Jerome Ringo's Form 4 filing for Ocean Biomedical, Inc. (OCEA).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 17 Feb 2023, 19:21.
Jerome Ringo - 15 Feb 2023 Form 4 Insider Report for Ocean Biomedical, Inc. (OCEA)
- Reporting relationship
- Director
- Issuer ticker
- OCEA
- Reported as of
- 15 Feb 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 17 Feb 2023, 19:21:39 UTC
- Prior SEC filing
- 17 Feb 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Katherine E. Spiser, as attorney-in-fact for Jerome Ringo
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Jerome Ringo filed Form 4 for Ocean Biomedical, Inc. (OCEA) on 17 Feb 2023.
Change
- Previous filing in this sequence was filed on 17 Feb 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
OCEA
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +75,000
- Change %
- Price
- $0.000000
- Shares after
- 75,000
- Date
- 15 Feb 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 75,000
- Exercise price
- $10.00
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Represents a right to purchase 75,000 shares of the common stock, par value $0.0001 per share (collectively, the "Option Shares"), of Ocean Biomedical, Inc. (the "Issuer") upon the exercise of a ten-year option granted to the Reporting Person as a non-employee director of the Issuer on February 15, 2023 under the Issuer's 2022 Stock Option and Incentive Plan. This option becomes exercisable in 36 monthly installments beginning on March 15, 2023, with 2,083 Option Shares becoming exercisable on each of the first 35 installments and the remaining 2,095 Option Shares becoming exercisable on the final installment, subject to the Reporting Person remaining in service as a member of the Issuer's board of directors on each installment date. This option is exercisable at an exercise price per Option Share equal to the greater of (i) $10, or (ii) the closing trading price of the Issuer's common stock on February 15, 2023, which was $6.06.
SEC remarks
Exhibit List - Exhibit 24.1: Power of Attorney (Jerome Ringo)